Friday 6-13-2014 Abbvie Inc. Common Stock (ABBV) $
Post# of 194
Posted On: 06/13/2014 11:49:23 PM
Friday 6-13-2014 Abbvie Inc. Common Stock (ABBV) $ABBV opened at 53.67 hitting the high price of 54.31 and a day low of 53.44 with a total volume of 4,413,075. ABBV had a previous close of 53.66 and has been seeing an average volume of 4,501,265.
Overall Average: 40% Buy
Recent stock forum discussions about ABBV http://investorshangout.com/search?q=ABBV&...mp;yt0=Go!
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. (full story)
Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to... (full story)
How the U.S. Government Makes Money on Cannabis
at The Street - Fri Jun 13, 10:30AM CDT
The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties. (full story)
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
PR Newswire - Fri Jun 13, 6:10AM CDT
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at: (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Bristol-Myers' RA Drug Orencia Encouraging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 5:10PM CDT
Bristol-Myers' Orencia performed well in a phase IIIb study as a combination therapy. (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland
PR Newswire Europe - Wed Jun 11, 5:48AM CDT
-- EUR85 million investment creates greater manufacturing capacity to deliver new medicines for patients (full story)
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris. (full story)
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas (full story)
Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious... (full story)
Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline. (full story)
Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in Achillion Pharmaceuticals got a double-whammy of good news over the last two days, with Merck 's purchase of fellow hepatitis c biotech Idenix pumping shares up over 40%. And Achillion is up over 50% today on further good news --... (full story)
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time. (full story)
Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ... (full story)
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic (full story)
Achillion Pharma Might be Next Hep C Takeout Target
at The Street - Mon Jun 09, 8:22AM CDT
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target. (full story)
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal
at The Street - Mon Jun 09, 7:27AM CDT
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from... (full story)
The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk... (full story)
Overall Average: 40% Buy
Recent stock forum discussions about ABBV http://investorshangout.com/search?q=ABBV&...mp;yt0=Go!
U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire - Fri Jun 13, 2:34PM CDT
AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. (full story)
Could This Buyout Go Down As One of the Worst Deals Ever?
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 13, 2:15PM CDT
You certainly don't have to look far these days to see that merger and acquisition activity is picking up across a number of sectors. Investors and Wall Street analysts love to see M&A activity because it signals two things. First, it points to... (full story)
How the U.S. Government Makes Money on Cannabis
at The Street - Fri Jun 13, 10:30AM CDT
The U.S. government holds a patent on cannabinoids and has collected money for licensing the patent. It could eventually collect thousands of dollars in royalties. (full story)
Equity Coverage on Pharma Industry -- Research on AbbVie, AcelRx Pharma, Bristol-Myers Squibb, and GW Pharma
PR Newswire - Fri Jun 13, 6:10AM CDT
The trading session on Thursday, June 12, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,734.19, down 0.65% and the NASDAQ Composite closed at 4,297.63, down 0.79%. The S&P 500 finished the day 0.71% lower at 1,930.11. The losses were broad based as eight out of the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index finished the day 0.56% lower at 688.58, while the index has gained 1.97% in the previous one month. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Bristol-Myers Squibb Co. (NYSE: BMY) and GW Pharmaceuticals PLC (NASDAQ: GWPH). Free technical research on ABBV, ACRX, BMY and GWPH can be downloaded upon signing up at: (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Expansions, New Leadership, Annual Award Winners, FDA Approvals, and Abstracts Presentations - Analyst Notes on AbbVie, Amgen, Regeneron Pharmaceuticals Inc, Valeant Pharmaceuticals and Lilly
PR Newswire - Thu Jun 12, 5:40AM CDT
Today, Analysts Review released its analysts' notes regarding AbbVie Inc. (NYSE: ABBV), Amgen, Inc. (NASDAQ: AMGN), Regeneron (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc (NYSE: VRX) and Eli Lilly and Co (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3638-100free. (full story)
Bristol-Myers' RA Drug Orencia Encouraging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 5:10PM CDT
Bristol-Myers' Orencia performed well in a phase IIIb study as a combination therapy. (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland
PR Newswire Europe - Wed Jun 11, 5:48AM CDT
-- EUR85 million investment creates greater manufacturing capacity to deliver new medicines for patients (full story)
AbbVie Presents Results from Large Global Study of Patient Attitudes and Adherence Across Six Chronic Inflammatory Diseases
PR Newswire - Wed Jun 11, 1:00AM CDT
AbbVie (NYSE:ABBV) today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results were presented today at the European League Against Rheumatism (EULAR) 2014 Congress in Paris. (full story)
AbbVie Announces Michael Severino, M.D. to Lead R&D Organization and Drive Continued Pipeline Advancement
PR Newswire Europe - Tue Jun 10, 11:46PM CDT
-- New Chief Scientific Officer Brings Wealth of Experience in Biotech and Key Therapeutic Areas (full story)
Will Merck's Bold Hepatitis C Play Pay Off?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 10, 1:30PM CDT
There is a significant (and sometimes larger than expected) gap between "looks like it can compete" and actually competing with a rival that has both strong data and a big head start, but Merck continues to show that it is serious... (full story)
Idenix Skyrockets on Merck Acquisition Deal, Focus on HCV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 12:10PM CDT
Merck's (MRK) decision to acquire Idenix (IDIX) for $24.50 per share in cash will boost its hepatitis C virus (HCV) pipeline. (full story)
Up 58%: Should You Buy Achillion Pharmaceuticals Today?
Michael Douglass and Matt Trogdon, The Motley Fool - Motley Fool - Tue Jun 10, 10:09AM CDT
Investors in Achillion Pharmaceuticals got a double-whammy of good news over the last two days, with Merck 's purchase of fellow hepatitis c biotech Idenix pumping shares up over 40%. And Achillion is up over 50% today on further good news --... (full story)
AbbVie to Present at Goldman Sachs 35th Annual Global Healthcare Conference
PR Newswire - Tue Jun 10, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 10:40 a.m. Central time. (full story)
Here's Why Merck Paid Triple the Price for Idenix
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Mon Jun 09, 6:15PM CDT
U.S. stocks put in another record high on Monday -- the ninth in 11 trading sessions -- as the benchmark S&P 500 and the narrower Dow Jones Industrial Average both rose 0.1%. The technology-heavy Nasdaq Composite Index gained 0.4%. ... (full story)
Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014
M2 - Mon Jun 09, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx5qq/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Celltrion, Inc. - Biocon Limited - Pfizer Inc. - UCB S.A. - Sandoz Inc. - Swedish Orphan Biovitrum AB - Biosidus S.A. - Genor BioPharma Co., Ltd. - AbbVie Inc. - Epirus Biopharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/zrx5qq/idiopathic (full story)
Achillion Pharma Might be Next Hep C Takeout Target
at The Street - Mon Jun 09, 8:22AM CDT
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target. (full story)
Merck Buys Idenix for $3.9B in Yet Another Blockbuster Hep C Deal
at The Street - Mon Jun 09, 7:27AM CDT
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from... (full story)
The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk... (full story)
(0)
(0)AbbVie Inc. (ABBV) Stock Research Links
Scroll down for more posts ▼